Radiopharmaceutical Theranostics Market Overview
The Radiopharmaceutical Theranostics Market is gaining momentum as healthcare systems increasingly adopt precision diagnostics and targeted radionuclide therapies. Theranostics combines molecular imaging with patient-specific treatment selection, enabling clinicians to identify disease targets and use corresponding radiopharmaceutical therapies. Growing cancer prevalence, advances in nuclear medicine, development of novel radioisotopes, and increasing emphasis on personalized medicine are supporting market expansion.
The broader global Radiopharmaceuticals Market was valued at USD 7.09 Billion in 2024 and is projected to grow from USD 7.737 Billion in 2025 to USD 18.52 Billion by 2035, exhibiting a CAGR of 9.12% during 2025–2035. North America led the market with more than 45% share in 2024. The theranostics segment is benefiting from increasing use of targeted radiopharmaceuticals in oncology and continued advances in PET, SPECT, radiochemistry, and radioligand therapy.
Unlock Exclusive Insights – Request Your Free Sample Report Now!
https://www.marketresearchfuture.com/reports/radiopharmaceutical-theranostics-market-27107
Key market players driving innovation and competitiveness in the Radiopharmaceutical Theranostics Market include:
Novartis AG
Bayer AG
Cardinal Health
GE HealthCare
Siemens Healthineers
Lantheus Medical Imaging
Bracco Imaging
NorthStar Medical Radioisotopes
Elekta AB
Telix Pharmaceuticals
The market is being driven by increasing demand for targeted cancer treatment, rising adoption of molecular imaging, and advances in radioligand therapies. Diagnostic radiopharmaceuticals remain a major foundation for theranostic workflows because they help identify molecular targets and assess disease distribution. Therapeutic radiopharmaceuticals are gaining momentum as more targeted agents reach clinical use. Hospitals and specialized nuclear medicine centers remain important end users because theranostic procedures require specialized imaging, radiopharmacy, radiation-safety, and clinical infrastructure.
The Radiopharmaceutical Theranostics Market can be viewed across multiple dimensions. Based on Application Outlook, it includes Oncology, Neurology, Cardiology, and Other Therapeutic Areas. In terms of Radiopharmaceutical Type, the market includes Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals. The Imaging Modality Outlook comprises PET and SPECT, while the Therapeutic Modality Outlook includes radioligand therapy and other targeted radionuclide approaches. By End User, the market includes Hospitals, Diagnostic Imaging Centers, Research Institutions, and Specialized Nuclear Medicine Centers. Regionally, the market is analyzed across North America, Europe, Asia Pacific, South America, and the Middle East and Africa.
Purchase the Complete Report for Strategic Insights and Market Forecasts:
https://www.marketresearchfuture.com/reports/radiopharmaceutical-theranostics-market-27107
The expansion of theranostic approaches in oncology is creating significant opportunities for radiopharmaceutical developers, nuclear pharmacies, imaging providers, and healthcare institutions. Novel isotopes such as lutetium-177, gallium-68, actinium-225, and other emerging radionuclides are broadening research and clinical possibilities. Investments in isotope production, radiopharmacy infrastructure, automated manufacturing, and supply-chain capabilities are also becoming increasingly important as demand for radiopharmaceuticals rises.
Recent Developments:
Novartis continues to expand its radioligand therapy capabilities, supporting the development and manufacturing of targeted radiopharmaceutical treatments.
Bristol Myers Squibb completed its acquisition of RayzeBio in 2024, strengthening its position in targeted radiopharmaceutical and actinium-based therapy development.
Radiopharmaceutical manufacturers are increasing investment in production capacity for therapeutic and diagnostic isotopes to support growing clinical demand.
Research programs are advancing theranostic pairs that combine diagnostic imaging agents with corresponding therapeutic radionuclides for patient selection and treatment monitoring.
Healthcare providers are expanding nuclear medicine capabilities as targeted radioligand therapies and molecular imaging become increasingly integrated into precision oncology.
Browse In-depth Market Research Report (Pages, Charts, Tables, Figures):
https://www.marketresearchfuture.com/reports/radiopharmaceutical-theranostics-market-27107
Reasons to Buy the Report:
Provides comprehensive insights into the Radiopharmaceutical Theranostics Market dynamics, trends, opportunities, and growth potential.
Helps identify emerging opportunities across oncology, neurology, cardiology, molecular imaging, and targeted radionuclide therapy.
Offers detailed segmentation analysis across applications, radiopharmaceutical types, imaging modalities, end users, and regions.
Includes competitive intelligence covering leading radiopharmaceutical, nuclear medicine, imaging, and pharmaceutical companies.
Assists investors and stakeholders in making informed decisions supported by market forecasts, technology trends, clinical developments, and regional analysis.
Future Outlook:
The future of the Radiopharmaceutical Theranostics Market will be shaped by continued advances in molecular imaging, radioligand therapy, radioisotope production, and personalized medicine. The growing use of diagnostic agents to identify molecular targets and select patients for corresponding therapies should strengthen theranostic workflows. Oncology is expected to remain a major growth area, while research into neurological, cardiovascular, and other targeted applications may broaden the market. Continued investment in isotope production, radiopharmacy networks, manufacturing automation, and specialized clinical infrastructure should support long-term adoption.
➤➤Explore MRFR’s Related Ongoing Coverage In Healthcare Domain:
US Radio Pharmaceutical Market
Radiopharmaceuticals Distribution Market
Nuclear Medicine Imaging Market
Positron Emission Tomography Market
